Skip to content
OpenCapital
Get started

Pacira BioSciences, Inc. PCRX SG&A

SG&A at other companies

Avanos Medical logo
Avanos MedicalAVNS
$77.7M+2.6%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$86.35M+13.0%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-16.0%
Enterprise value$1.21B+1.2%
P/E183.5×—
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%—
Net margin0.7%—
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%—
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s SG&A?
Pacira BioSciences, Inc. (PCRX) reported SG&A of $93.94M in Q1 2026.
How has Pacira BioSciences, Inc.'s SG&A changed year-over-year?
Pacira BioSciences, Inc.'s SG&A increased by 8.3% year-over-year, from $86.78M to $93.94M.
What is the long-term trend for Pacira BioSciences, Inc.'s SG&A?
Over 4 years (2021 to 2025), Pacira BioSciences, Inc.'s SG&A has grown at a 16.6% compound annual growth rate (CAGR), from $199.35M to $368.76M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.